

Notice: This is a translation of a notice in Japanese and is made solely for the convenience of foreign shareholders.

In the case of any discrepancy between the translation and the Japanese original, the latter shall prevail.

May 25, 2026

To Shareholders,

Company Name: Renascience Inc.  
Representative: Toshio Miyata, Chairman and CEO  
(Code: 4889 TSE Growth)  
For inquiries, please contact Administration Dept.

**Notice Regarding Reduction of Capital Reserve and Disposition of Surplus**

We hereby announce that, at the meeting of the Board of Directors held on May 25, 2026, the Company resolved to submit a proposal regarding the reduction of capital reserve and disposition of surplus to the 27th Annual General Meeting of Shareholders scheduled to be held on June 25, 2026 (the "Annual General Meeting of Shareholders"), as follows:

1. Purpose of the reduction of capital reserve and disposition of surplus

As of March 31, 2026, the Company had capital reserve of 2,402,847,540 yen, while recording a deficit in retained earnings brought forward of 1,136,328,774 yen. Accordingly, as described below, the Company will reduce the amount of capital reserve and dispose of surplus in order to cover the deficit and improve the soundness of its financial position.

Specifically, pursuant to Article 448, Paragraph 1 of the Companies Act, the Company will reduce the amount of capital reserve and transfer the reduced amount to other capital surplus. In addition, pursuant to Article 452 of the Companies Act, the Company will transfer 1,136,328,774 yen from the increased other capital surplus to retained earnings brought forward to offset the deficit. If the stock acquisition rights issued by the Company are exercised by the effective date of this matter, the amounts of stated capital, capital reserve, and each item in the net assets section after implementation set forth below may change.

This matter does not involve any payment to shareholders. Since the reduction of capital reserve will be implemented without changing the total number of issued shares, it will not affect the number of shares held by shareholders. In addition, because the reduction of capital reserve will not change the Company's net assets or the total number of issued shares, it will not result in any change in net assets per share.

2. Details of the reduction of capital reserve

Pursuant to Article 448, Paragraph 1 of the Companies Act, the Company will reduce the amount of capital reserve and transfer the reduced amount to other capital surplus.

(1) Amount of capital reserve to be reduced

1,136,328,774 yen out of capital reserve of 2,402,847,540 yen

(2) Amount of other capital surplus to be increased

1,136,328,774 yen

### 3. Details of the disposition of surplus

Subject to the reduction of capital reserve taking effect, pursuant to Article 452 of the Companies Act, the Company will reduce 1,136,328,774 yen of the increased other capital surplus, transfer such amount to retained earnings brought forward, and apply it to cover the deficit.

(1) Item and amount of surplus to be decreased

Other capital surplus: 1,136,328,774 yen

(2) Item and amount of surplus to be increased

Retained earnings brought forward: 1,136,328,774 yen

### 4. Net assets after the reduction of capital reserve and disposition of surplus

(Thousands of yen; amounts less than one thousand yen are rounded down)

Item	As of March 31, 2026	After implementation
Shareholders' equity	3,310,086	3,310,086
Stated capital	1,982,422	1,982,422
Capital surplus	2,464,010	1,327,681
Capital reserve	2,402,847	1,266,518
Other capital surplus	61,162	61,162
Retained earnings	△1,136,328	-
Other retained earnings	△1,136,328	-
Retained earnings brought forward	△1,136,328	-
Treasury shares	△17	△17
Stock acquisition rights	12,591	12,591
Total net assets	3,322,677	3,322,677

### 5. Schedule for the reduction of capital reserve and disposition of surplus

(1) Date of Board of Directors resolution May 25, 2026

(2) Date of Annual General Meeting of Shareholders resolution June 25, 2026 (scheduled)

(3) Date of public notice for submission of objections by creditors June 26, 2026 (scheduled)

(4) Final date for submission of objections by creditors July 31, 2026 (scheduled)

(5) Effective date August 7, 2026 (scheduled)

### 6. Outlook

This matter is a reclassification among accounts within net assets and will not change the amount of net assets or affect the Company's business results. This matter is subject to approval at the Annual General Meeting of Shareholders and other conditions.